Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
The pharmacokinetics of a single oral dose of 1.75 mg glibenclamide were studied in 15 healthy Caucasians including five poor metabolisers of debrisoquine and five poor metabolisers of S-mephenytoin. Plasma glibenclamide concentrations and the urinary concentrations of trans-4- and cis-3-hydroxyglibenclamide were analyzed by h.p.l.c. Thirty-six +/- 6% (mean +/- s.d., n = 15) of the given dose of glibenclamide was excreted in 48 h urine as hydroxylated metabolites, 27 +/- 4% as trans-4-hydroxyglibenclamide and 8 +/- 2% as cis-3-hydroxyglibenclamide. There were no differences in the plasma pharmacokinetics of glibenclamide or in the urinary excretion of the metabolites between poor and extensive metabolisers of debrisoquine, neither between the two mephenytoin hydroxylator phenotypes. The study thus indicates that the disposition of glibenclamide is not influenced by these two independent polymorphisms of drug oxidation.
Dahl-Puustinen
M L
ML
Department of Clinical Pharmacology, Huddinge University Hospital, Sweden.
Alm
C
C
Bertilsson
L
L
Christenson
I
I
Ostman
J
J
Thunberg
E
E
Wikström
I
I
D000328:Adult; D003647:Debrisoquin / Q000378:metabolism* / Q000493:pharmacokinetics; D005260:Female; D005905:Glyburide / Q000378:metabolism* / Q000493:pharmacokinetics; D006801:Humans; D006900:Hydroxylation; D008297:Male; D008617:Mephenytoin / Q000378:metabolism* / Q000493:pharmacokinetics; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010641:Phenotype; D011110:Polymorphism, Genetic
D008617:Mephenytoin; D005905:Glyburide; D003647:Debrisoquin